middle.news

Can Universal Biosensors Overcome Cash Crunch Despite 6% Revenue Growth?

2:44am on Monday 2nd of June, 2025 AEST Healthcare
Read Story

Can Universal Biosensors Overcome Cash Crunch Despite 6% Revenue Growth?

2:44am on Monday 2nd of June, 2025 AEST
Key Points
  • 6% year-over-year revenue growth driven by Sentia and Petrackr products
  • Net loss widened to A$3.84 million amid increased R&D spending
  • Laboratory testing services revenue declined 22% due to leadership challenges
  • Cash and equivalents at A$4.92 million, runway only into Q3 2025
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Universal Biosensors (ASX:UBI)
OPEN ARTICLE